Iorio A, Stonebraker JS, Chambost H, et al. - In this random-effects meta-analysis of registry data, researchers estimated hemophilia prevalence and prevalence at birth as well as if there is a related disadvantage in life expectancy. Participants were male patients with hemophilia A or B. Data reported that prevalence (per 100,000 males) is 17.1 cases for all severities of hemophilia A (6.0 cases for severe hemophilia A) and 3.8 cases for all severities of hemophilia B (1.1 cases for severe hemophilia B). Birth prevalence (per 100,000 males) is 24.6 cases for all severities of hemophilia A (9.5 cases for severe hemophilia A) and 5.0 cases for all severities of hemophilia B (1.5 cases for severe hemophilia B). For high-income countries, the life expectancy disadvantage is 30% for hemophilia A (37% for severe hemophilia A) and 24% for hemophilia B (27% for severe hemophilia B). Worldwide, the anticipated number of hemophilia patients is 1,125,000, with severe hemophilia expected to occur in 418,000 of them. The authors concluded that hemophilia prevalence is greater than estimated earlier, and there is still a life expectancy disadvantage in these patients. Establishing birth prevalence is a milestone in evaluating years of lost life, years of disability life and disease burden.